Bivalirudin (Angiomax) as a procedural anticoagulant in the pediatric population undergoing intravascular procedures for congenital heart disease.

Trial Profile

Bivalirudin (Angiomax) as a procedural anticoagulant in the pediatric population undergoing intravascular procedures for congenital heart disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2011

At a glance

  • Drugs Bivalirudin (Primary)
  • Indications Congenital heart defects; Embolism and thrombosis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 16 Oct 2008 Primary outcome added as reported by ClinicalTrials.gov.
    • 16 Oct 2008 Actual start date changed from Sep 2007 to Aug 2007 as reported by ClinicalTrials.gov.
    • 16 Oct 2008 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top